Researcher
An Wouters
- Research Expertise:* Coordinator of research lines focussing on targeted and combination therapy * Basic and translational research focussed on innovative combination strategies with targeted therapies for solid tumors and on unravelling resistance mechanisms
- Keywords:ONCOLOGY, TUMOR BIOLOGY, PRECLINICAL RESEARCH, CANCER THERAPY, Biomedical sciences (incl. biochemistry)
- Disciplines:Cancer biology, Cancer therapy
- Research techniques:* in vitro cell culture * cytotoxicity assays, radiation research, combination therapies * cellular and molecular techniques for detection of apoptosis, cell cycle distribution, protein expression, protein phosphorylation,...
- Users of research expertise:scientific researchers, teachers, physicians, people interested in cancer research
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Oct 2004 → 31 Dec 2018
Projects
1 - 10 of 22
- Targeting therapy-induced senescence in non-small cell lung cancer: development and optimization of a novel triple-step, senescence-focused treatment strategy.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Fundamental insights in the immunosuppressive metabolic effects of the hypoxic tumor microenvironment on natural killer cells in head and neck squamous cell carcinoma.From1 Nov 2023 → TodayFunding: FWO fellowships
- Metabolic rewiring of natural killer cells for enhanced functioning in the tumour microenvironment.From1 Sep 2023 → TodayFunding: IOF - technology concept exploration
- Targeting therapy-induced senescence in non-small cell lung cancer: development and optimization of a novel triple-step, senescence-focused treatment strategy.From1 Nov 2022 → 31 Oct 2023Funding: BOF - doctoral mandates
- High-end comprehensive GCxGC-QTOF-MS research facility for volatile and semivolatile compounds (GALILEO).From1 Jun 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- FLASH radiation therapy to improve the therapeutic management of breast cancer by reducing radiationinduced skin, soft tissue, lung and heart toxicities.From1 Apr 2022 → TodayFunding: Nonprofit institution or equivalents
- Combining targeted therapy and immunotherapy to improve survival and quality of life of head and neck cancer patients.From1 Mar 2021 → TodayFunding: Nonprofit institution or equivalents
- Gasping for air in the leukemic bone marrow: improving the functioning of natural killer cells in hypoxia.From23 Sep 2020 → 22 Sep 2021Funding: Foundations, funds and other with scientific goal
- Novel, rationally designed combination strategies, based on genomic and proteomic analyses, to enhance the response to cetuximab therapy in head and neck cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Unraveling of the role and the regulation of hypoxia-inducible factors in natural killer cell functioning in hypoxic and stimulating environments.From1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
Publications
21 - 30 of 70
- The art of obtaining a high yield of cell-free DNA from urine(2020)
Authors: Elien Augustus, Kaat Van Casteren, Laure Sorber, Peter Van Dam, Geert Roeyen, Marc Peeters, Alex Vorsters, An Wouters, Christian Rolfo, Karen Zwaenepoel, et al.
- Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status(2020)
Authors: Hasan Baysal, Ines De Pauw, Hannah Zaryouh, Jorrit De Waele, Marc Peeters, Patrick Pauwels, Jan Vermorken, Evelien Smits, Filip Lardon, Julie Jacobs, et al.
Pages: 1 - 10 - The potential and controversy of targeting STAT family members in cancer(2020)
Authors: Yannick Verhoeven, Sam Tilborghs, Julie Jacobs, Jorrit De Waele, Delphine Quatannens, Christophe Deben, Hans Prenen, Patrick Pauwels, Xuan Bich Trinh, An Wouters, et al.
Pages: 41 - 56 - The benefit of reactivating p53 under MAPK inhibition on the efficacy of radiotherapy in melanoma(2019)
Authors: Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Stephane Simon, Francois Sales, Fabrice Journe, Ahmad Awada, Ghanem E. Ghanem, Dirk Van Gestel
- RANK-RANKL signaling in cancer of the uterine cervix(2019)
Authors: Peter Van Dam, Yannick Verhoeven, Julie Jacobs, An Wouters, Wiebren Tjalma, Filip Lardon, Tim Van den Wyngaert, Evelien Smits, Cecile Colpaert, Hans Prenen, et al.
- In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53(2019)
Authors: Jolien Van den Bossche, Christophe Deben, Ines De Pauw, Hilde Lambrechts, Christophe Hermans, Julie Jacobs, Pol Specenier, Patrick Pauwels, Jan Vermorken, Marc Peeters, et al.
Pages: 1196 - 1213 - Overcoming intrinsic and acquired resistance to EGFRtargeting agents in cancer treatment(2019)
Authors: Ines De Pauw, An Wouters, Filip Lardon, Marc Peeters
Number of pages: 305 - Radiosensitization of non-small cell lung cancer cells by the Plk1 inhibitor volasertib is dependent on the p53 status(2019)
Authors: Andreas Domen, Marc Peeters, Ines De Pauw, Julie Jacobs, Sven De Bruycker, Pol Specenier, Patrick Pauwels, Jan Vermorken, An Wouters
- RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment(2019)
Authors: Peter Van Dam, Yannick Verhoeven, Xuan Bich Trinh, An Wouters, Filip Lardon, Hans Prenen, Evelien Smits, Marcella Baldewijns, Martin Lammens
Pages: 85 - 91 - Preclinical investigation of strategies to bolster immunotherapy for glioblastoma(2019)
Authors: Jorrit De Waele, Evelien Smits, An Wouters
Number of pages: 271